New pharmacologic strategies for acute neuronal injury

M S Luer1, D H Rhoney, M Hughes

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock 72205, USA.

Pharmacotherapy
|September 1, 1996
PubMed

Insights

New drugs for neurotrauma are expanding, targeting secondary injury mechanisms like ionotropic channel antagonism and lipid peroxidation. Clinical trials are underway to confirm the efficacy of these promising neuroprotective agents.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurosurgery

Background:

  • Secondary injury mechanisms in neurotrauma are increasingly understood.
  • This evolving knowledge provides a basis for developing new therapeutic agents.
  • Key targets include ionotropic channels, lipid peroxidation, and neurotrophic factors.

Purpose of the Study:

  • To review the expanding landscape of new drugs for neurotrauma treatment.
  • To highlight emerging therapeutic strategies based on secondary injury mechanisms.
  • To discuss the current status of these agents in clinical trials.

Main Methods:

  • Literature review of recent advancements in neurotrauma drug development.
  • Analysis of emerging theories on secondary neuronal injury.
  • Identification of promising therapeutic targets and agents.

Main Results:

  • A growing number of novel drugs are being developed for neurotrauma.
  • Interventions targeting ionotropic channel antagonism, lipid peroxidation inhibition, and neurotrophic factor augmentation show promise.
  • Several agents are currently in various phases of clinical trials.

Conclusions:

  • The development of neuroprotective drugs is rapidly advancing.
  • Targeting specific secondary injury pathways offers significant therapeutic potential.
  • Clinical validation is crucial for establishing the role of these agents in neurotrauma therapy.

Related Concept Videos

Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...